Head and neck cancer | Flatiron Health

Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort →

Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM

May 2020

AACR Annual Meeting

Real-world treatment patterns and time on treatment (rwToT) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on or after platinum-containing chemotherapy in United States (U.S.) →

Chirovsky, D, Zhiwen, L, Yu, F, Baxi, SS, Chandwani, S, Joo, S, Ramakrishnan, K

February 2020

Multidisciplinary Head and Neck Cancers Symposium

Flatiron-authored

A comparison of patient characteristics treated with nivolumab for recurrent/metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) in Germany and the USA →

von der Hyde, E, Welslau, M, Gauler, T, Rothni,e K, Waldenberger, D, Deitz, A

November 2019

EU ISPOR

Real-world treatment patterns of patients with recurrent/metastatic head and neck squamous cell carcinoma who were eligible for second-line therapy after platinum-based chemotherapy →

Seal, B, Sun, P, Wang, H

October 2019

AMCP Nexus

Real-world survival and treatment patterns of patients with recurrent/metastatic head and neck squamous cell carinoma who were eligible for first-line therapy →

Sun, P, Seal, B, Wang, H

October 2019

AMCP Nexus

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors →

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

ASCO Annual Meeting

Flatiron-authored